Smoking marijuana or ingesting it can make you feel relaxed or “high”. Why is that? Tetrahydrocannabinol, also called THC, is the chemical responsible for marijuana’s psychological effects. Marijuana contains anywhere from 5-30% THC content. Hemp, on the other hand, is regulated to only contain a max THC level of 0.3%, essentially making it impossible to get a “high” from smoking or otherwise ingesting. However, hemp contains high cannabidiol (CBD) content.
CBD was has been found to have analgesic, anti-inflammatory, and anti-anxiety properties without any psychoactive effects. Thus, it has recently gained popularity as a medical supplement and is now one of the leading applications of hemp in the US.
If passed, the 2018 Farm Bill would officially remove hemp from the DEA’s list of controlled substances. This legislation would enable the CBD Industry to thrive by permitting domestic farmers to enter the market, open up more research and clinical trials, investment opportunities, and even federal crop insurance.
Cancer Research and Clinical Trials for CBD
In recent years, cancer researchers have been examining the effects of CBD on cancer patients. Important clinical studies are going on right now exploring the uses of CBD to learn if it can reduce nausea and vomiting linked to chemotherapy, be used to relieve chronic pain and for use in palliative care. Researchers are actively investigating CBD as a stand-alone therapy or one to be used with other cancer treatment protocols such as radiation treatment and/or chemotherapy. No longer are people just hoping for a cure, they’re waiting for a breakthrough.
Overall, the U.S. National Library of Medicine currently lists 62 cannabidiol studies in progress and 21 completed studies. While not all of these are focused on cancer research, scientists are looking to CBD as an important medical element to be utilized in numerous types of cancer, various disorders and conditions.
What the American Cancer Society Has to Say About CDB
“More recently, scientists reported that THC and other cannabinoids such as CBD slow growth and/or cause death in certain types of cancer cells growing in lab dishes. Some animal studies also suggest certain cannabinoids may slow growth and reduce spread of some forms of cancer.
There have been some early clinical trials of cannabinoids in treating cancer in humans and more studies are planned. While the studies so far have shown that cannabinoids can be safe in treating cancer, they do not show that they help control or cure the disease.”
Getting CBD to Market
Before any company can get a drug on the market, the FDA requires special authorization. The FDA new drug application process can be a grueling 17-month long period in which 93% of applicants are rejected on the first round. Resubmission results in a 66% rejection rate.
The challenges are not over once approved. The successful clinical development of a drug, from preclinical testing to marketing approval, requires a large amount of resources and money. The estimated development cost of a single drug is approximately $2.6 billion; however, they can run upwards of $12 billion. It also can take 10 years before a drug meets final approval from the FDA for distribution and sale.
While the Food and Drug Administration ultimately approves less than one of every 10 drugs that enter clinical trials, this does not stop dedicated scientists and researchers from driving forward efforts to learn about new therapeutic or curative treatment protocols for CBD in cancer clinical trials.
About Diverse Biotechl, Inc.
Diverse Biotech Inc. is an innovative, clinical-stage biopharmaceutical research company, committed to discovering and developing novel therapeutics from its proprietary cannabinoid product platform.
For more information on Diverse Biotech or its Cannabinoid (CBD) clinical trials, use in the treatment of specific types of malignancies related to glioblastoma, myeloma, gastrointestinal, and breast cancer, when administered in conjunction with Standard of Care, please contact Diverse Biotech by phone at 407-776-9217 or visit the company’s headquarters at 805 S. Kirkman Rd, Suite 202, Orlando, Florida 32811.